Press Releases 10.20.2008
T2 Biosystems Appoints Pamela Weagraff as Vice President, Regulatory and Quality
CAMBRIDGE, Mass.--(BUSINESS WIRE)--T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance (MR) technology, today announced the appointment of Pamela J. Weagraff, RAC to the newly created position of Vice President, Regulatory and Quality.
“We are delighted to attract an executive of Pam’s caliber, who has more than 20 years of experience in product management, regulatory and quality medical technology commercialization,” said John McDonough, CEO of T2 Biosystems. “We are pleased she is joining our team as we begin preparing for our entry to market with our novel technology that has the potential to revolutionize medical diagnostics and dramatically improve patient care by enabling immediate, accurate testing for almost any health condition, in nearly any setting.”
Prior to joining T2 Biosystems, Ms. Weagraff most recently served as Principal Consultant with Quintiles Consulting, assisting early stage medical technology start-ups in development and implementation of customer-focused regulatory, clinical and quality strategies and plans. Prior to her consulting work, Ms. Weagraff was Vice President, Regulatory, Clinical and Quality, for the privately held company MediSpectra, Inc., as well as held a 15-year tenure at Hewlett Packard’s Medical Products Group (now Philips Medical) and SmithKline Beckman (now GlaxoSmithKline) in a variety of management positions in product marketing, regulatory, clinical and quality efforts.
Ms. Weagraff’s contributions to medical technology have been nationally recognized with an AdvaMed Management Fellowship and as a recipient of Vice President Al Gore’s Hammer Award from the National Partnership for Reinventing Government. She currently serves as Regulatory Advisor to the MassMEDIC Board of Directors. Ms. Weagraff received her B.A. degree from Pennsylvania State University and her M.B.A. degree from Boston University.
T2 Biosystems is developing the next generation of medical diagnostic products through its proprietary technology, which combines nanotechnology and the miniaturization of proven MR technology to develop rapid, accurate and portable diagnostics. T2 Biosystems’ technology has been validated in multiple published journal articles and has shown to accurately analyze viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets. The Company is developing a pipeline of diagnostic products based on its technology, including devices for hospitals, diagnostic laboratories and medical offices, as well as individual patients.
About T2 Biosystems
T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.t2biosystems.com.
Yates Public Relations
Kathryn Morris, 845-635-9828